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Peering into the ﬁeld of Alzheimer’s disease (AD), the outsider realizes that many of the
therapeutic strategies tested (in animalmodels) have been successful. One alsomay notice
that there is a deﬁcit in translational research, i.e., to take a successful drug in mice and
translate it to the patient. Efforts are still focused on novel projects to expand the therapeutic
arsenal to “cure mice.” Scientiﬁc reasons behind so many successful strategies are not
obvious. This article aims to review the current approaches to combat AD and to open a
debate on common mechanisms of cognitive enhancement and neuroprotection. In short,
either the rodent models are not good and should be discontinued, or we should extract
the most useful information from those models. An example of a question that may be
debated for the advancement in AD therapy is: In addition to reducing amyloid and tau
pathologies, would it be necessary to boost synaptic strength and cognition? The debate
could provide clues to turn around the current negative output in generating effective
drugs for patients. Furthermore, discovery of biomarkers in human body ﬂuids, and a
clear distinction between cognitive enhancers and disease modifying strategies, should
be instrumental for advancing in anti-AD drug discovery.
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INTRODUCTION
In humans, there are only two types of drugs approved for
Alzheimer’s disease (AD) that unfortunately are not of much relief:
acetyl cholinesterase inhibitors and modulators of N-methyl-D-
aspartate (NMDA) receptors. In animals, however, every other
treatment tested has been successful. The vast amount of effort
devoted to ﬁnd a cure or a relief to AD patients, i.e., to translate
pre-clinical ﬁndings to the bedside, has been to date fruitless. It
is about time to covert the feeling of lost-in-translation research
into proﬁtable knowledge. Even if transgenics were good models
for human AD, it is intriguing that many different compounds
targeting different pathways enhance cognition (see Figure 1).
Careful analysis of why different approaches reduce symptoms
and/or degeneration in animals will surely help in accelerating
translational research and provide human-successful medications
to ﬁght the two sides of AD: neurodegeneration and cognitive dys-
function. Better animal models and good biomarkers for patient
subgrouping will be also instrumental for quick advancement in
theﬁeld. Thepaper revises all these aspectswith the aim to generate
debate among scientists.
ALZHEIMER’S DISEASE FEATURES
One of the distinguishing features of AD pathology is the deposi-
tion of Aβ-containing senile plaques and phospho-tau-containing
tangles in brain. The discovery of early-onset familial AD (FAD)
cases more than 20 years ago identiﬁed three relevant genes [amy-
loid precursor protein (APP) and presenilins 1 and 2, reviewed
in Tanzi et al., 1996]. Mutations in these genes cause an over-
production of beta-amyloid (Aβ) or of the longer Aβ peptides.
These genetic-based observations, together with the fact that indi-
viduals with Down’s syndrome1 show AD-like pathology in their
brain, have led the “amyloid cascade hypothesis” (Hardy and Hig-
gins, 1992) by which Aβ initiates a chain of events leading to
neuroinﬂammation, neurodegeneration, and clinical manifesta-
tions (memory loss and senile dementia). The amyloid cascade
hypothesis for AD has dominated the thoughts about the etiol-
ogy and pathogenesis of this disease, and guided the efforts to
ﬁnd treatments. It has been proposed that longer Aβ forms, i.e.,
amyloid peptides 1–42 or 1–43, are triggering factors for AD
(Sandebring et al., 2013). However, the differential toxicities of
Aβ forms have not been sufﬁciently addressed and alternative
hypotheses point to either ﬁbrils (Lorenzo and Yankner, 1994),
oligomers (Lambert et al., 1998), dimers (Shankar et al., 2008),
or soluble forms (Cleary et al., 2005) as the culprit. Similarly,
the relative abundance of the different Aβ species or conforma-
tions has not been determined in either FAD, sporadic AD or in
Down’s syndrome. Still, we have a relatively good understand-
ing of the mechanisms by which these rare genetic mutations
lead to AD. However, the precipitating factors that lead to the
accumulation of Aβ and also of hyperphosphorylated tau in the
much more common sporadic forms of AD are still unknown.
As of yet, there is no clear link between Aβ and tau patholo-
gies, as animals carrying FAD genes express huge amounts of
amyloid but show no tangle pathology. Also, a major unmet
scientiﬁc need in the AD ﬁeld is to understand the normal bio-
chemistry and biological function(s) of APP and its metabolites.
1Trisomy in the chromosome 21, where the APP gene is also present.
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Accordingly, the potential risks of targeting Aβ production (in
the brain and the periphery) are yet undetermined. Although
the reported pathological effects of Aβ are numerous (to date,
2633 articles for “Aβ toxicity” are in Pubmed), senile plaques
and Aβ were even looked as protective adaptations to AD (Lee
et al., 2004). In parallel to the toxic effects in a variety of cell
and animal models, Aβ may activate kinases (Vestling et al.,
1999; Cedazo-Minguez and Cowburn, 2001; Tabaton et al., 2010),
act as antioxidant (Zou et al., 2002), have anti-microbial activ-
ity (Soscia et al., 2010), or modulate cholesterol transport (Yao
and Papadopoulos, 2002). As β- (BACE1) and γ-secretases are
responsible for Aβ generation, efforts have been made to develop
inhibitors for clinical use in AD. However, increasing number
of studies reveals their role in the metabolism of multiple sub-
strates, which is a challenge to reach selectivity to only inhibit
Aβ production. Moreover, some substrates for these proteases
are important for neuronal cell biology. For example, BACE1
cleaves β subunits of voltage-gated sodium channels (Gersbacher
et al., 2010), and neuregulins, which are crucial molecules for
development and myelinization (Hu et al., 2006; Willem et al.,
2006). The same holds true for γ-secretase, a promiscuous di-
aspartyl protease responsible for the cleavage of diverse, type I
transmembrane proteins. To date, more than 90 proteins have
been identiﬁed as substrates of this enzyme (Haapasalo and
Kovacs, 2011). γ-secretase substrates have different structure,
localization, and regulate a wide variety of cellular events, such
as cell fate determination, adhesion, migration, neurite out-
growth, axon guidance, or formation andmaintenance of synapses
(Jurisch-Yaksi et al., 2013). Apart from APP, the most studied
γ-secretase substrate is Notch, a signaling molecule critically
required for development and cell fate determination. Drugga-
bility of γ-secretase has not been an issue, but selectivity to
inhibit only APP cleavage is a major problem. In addition to
decreasing Aβ, γ-secretase inhibitors affect many proteins inhibit-
ing production of functionally important C-terminal peptides,
an outcome with potentially toxic consequences. Therefore, new
strategies are needed to develop agents selectively inhibiting cleav-
age of APP without affecting other substrates. These efforts
were propelled by recent discoveries of modulators that con-
trol the γ-secretase cleavage of speciﬁc substrates by binding
and recruiting them to γ-secretase for processing (Barthet et al.,
2012).
The APP primary structure strongly suggests that its nor-
mal function relates to cell–cell interaction and cell–substrate
adhesion processes consistent with a role in development. Fur-
thermore, APP involvement has been reported in cell migration
(Rice et al., 2012), trafﬁcking and signaling (Aydin et al., 2012),
neuronal calcium homeostasis and synaptic transmission (Octave
et al., 2013), and iron-mediated neurotrophic properties (Duce
et al., 2010). Targeting the metabolism of APP to reduce Aβ pro-
duction will also affect the production of other APP metabolites
(i.e., sAPP or the amyloid precursor protein intracellular domain,
AICD). AICD has more than 20 interacting protein partners,
which connect APP to different intracellular signaling pathways
including regulation of transcription, apoptosis, and cytoskeletal
dynamics (Cowburn et al., 2007; Pardossi-Piquard and Checler,
2012).
FIGURE 1 | Cartoonial metaphor of the success in relieving the
cognitive deficits of AD mouse models. A variety of different compounds
are proven successful as cognitive enhancers and neuroprotetive in
transgenic AD models. Copyright retained by Nuria Franco
(franconuria@gmail.com).
ANTI-AMYLOID AND ANTI-PHOSPHO-TAU APPROACHES
Studies in animal AD models have suggested that removal of Aβ
and/or decreasing its production are good strategies for anti-AD
therapy. Unfortunately, the numerous clinical trials with agents
targeting amyloid have failed to reach the primary clinical end-
points. In the last 3/4 years, four additional clinical trials along
this line (inhibition of γ-secretase by semagacestat and avagace-
stat, and two different anti-Aβ antibodies, bapineuzumab and
solanezumab) gave ambivalent results with no obvious positive
ﬁndings. At present, the AD ﬁeld is considering whether persevere
with Aβ targeting or concentrate efforts and resources on other
approaches.
On-going studies such as the Alzheimer’s Prevention Initiative
(API) and the Dominantly Inherited Alzheimer Network (DIAN)
will determine if clearing Aβ from the brain is effective to treat
AD. API is an international public–private consortium established
to conduct research on an extended family of 5000 members in
Antioquia, Colombia (the world’s largest in which a gene for FAD
has been identiﬁed). DIAN is an international initiative funded
by the US National Institute on Aging (NIA) tracking participants
from families in which Alzheimer’s-causing mutations have been
identiﬁed. Targeting Aβ may be only successful for the early-onset
autosomal dominant types of the disease, where increasedAβ pro-
duction occurs from birth. For the majority of AD cases, where
amyloid accumulation is a later event resulting from unknown
causes, the strategy is probably not so straightforward.
Despite intraneuronal tangles constituted by abnormally
hyperphosphorylated tau are in direct correlation with neuronal
death andADprogression, they have historically been second play-
ers both to explain cognitive impairment and to be considered
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in therapy. In contrast to the APP gene, mutations in tau do not
causeAD,but fronto-temporal dementia (FTD;Goedert and Jakes,
2005). Tau pathology is present not only in AD but also in sev-
eral neurodegenerative disorders, pointing out to a central role
in the neuronal death mechanisms. In contrast to Aβ, the bio-
logical function of tau is well known. Tau regulates microtubule
assembly, dynamics, and spatial organization, it and participates
in the axonal transport of organelles and vesicles (Ebneth et al.,
1998). Tau-induced neurodegeneration is likely a consequence of
a loss of biological function together with the initiation of toxic
events. There is a strong correlation between tau phosphorylation
and tau pathology, and this has led to the rationale of develop-
ing tau kinase inhibitors as potential therapeutic agents (Medina
and Avila, 2010). Since there is not a single but multiple kinases
involved in generating hyperphosphorylated tau in vivo, there is
a debate about the potential efﬁcacy of targeting the different
kinases (Schneider and Mandelkow, 2008). Tau anti-aggregants
and tau-based immunotherapy are also being tested but so far
without success. For instance, the GSK3β inhibitor tideglusib,
tested in a 26-week Phase IIb trial for the treatment of circa 300
mild-to-moderate AD patients, failed to meet the primary cog-
nitive endpoint and two secondary endpoints (Medina and Avila,
2014).
As an alternative to kinase inhibition, activation of phos-
phatases has also been proposed as a strategy for reducing
tau phosphorylation. Protein phosphatase 2A (PP2A), the main
brain phosphatase, has received special attention. Treatment of
tau transgenic mice with the PP2A activator sodium selenate
reduced tauhyperphosphorylation and tangle formation, aswell as
improved memory and prevented neurodegeneration (Corcoran
et al., 2010). As PP2A has a broad substrate speciﬁcity, allosteric
activation of this enzyme to speciﬁcally reduce tau phosphory-
lation is a big challenge. Several other anti-tau treatments were
effective in preventing and intervening the progress of tau hyper-
phosphorylation in animal models, improving neuron function or
cognition, for example epithilone D (EpoD; Brunden et al., 2010)
or microtubule-stabilizing agents as davunetide (Matsuoka et al.,
2008). Disappointingly, a 12-week, placebo-controlled study with
intranasal davunetide was recently reported failing to detect a sta-
tistically signiﬁcant beneﬁt in 144 subjects with amnestic mild
cognitive impairment (Morimoto et al., 2013).
As in the Aβ ﬁeld, increasing efforts are being made to
design an effective vaccine against tau pathology. Few studies
regarding passive immunization against tau protein are currently
available (Panza et al., 2012). Also, several studies propose that
active immunization may be effective against tau in animal mod-
els (Medina and Avila, 2014). Very recently, the ﬁrst in-man
active anti-tau immunization studies have started (AADvac1;
http://clinicaltrials.gov/ct2/show/NCT01850238). Similarly to the
Aβ-based therapies, a number of key questions remain to be
answered in the tau-based immunotherapeutic approaches. Still,
we do not know which is the exact species to be targeted (aggre-
gation states, fragments, subtypes), or the mechanism of action
by which antibodies clear target molecules. The coming years
will tell if current anti-tau immunotherapeutic approaches are
effective or if they will be “lost in translation,” as in previous
immunization-based strategies.
Methylthioninium chloride (or methylene blue) was presented
in 2008 at the International Conference on Alzheimer’s Disease
(ICAD) held in Chicago. Methylene blue Phase II clinical trial
data suggested that it slowed decline in people with AD by roughly
4-points on the ADAS-Cog. However, methylene blue colors
the urine green, and pigments the eyes blue, which raises the
question of how the study could be performed blindly. A new
version of methylene blue is now heading toward phase 3 test-
ing, though in FTD. The mechanism of action of this compound
is unknown, but it has been speculated that it could act as anti-
tau aggregation agent. Some studies theorize that the compound
blocks aggregation of not only tau but also several other proteins
such as α-synuclein, TDP-43, or even Aβ (Sontag et al., 2012),
whereas other studies ﬁnd the compound to be ineffective (Van
Bebber et al., 2010). Other suggestions for methylene blue mode
of action were autophagy stimulation (Congdon et al., 2012) or
enhancement of proteasome activity (Medina et al., 2011).
THE DIABETES AND VASCULAR LINK TO AD
Even before FAD mutations were detected, epidemiological stud-
ies revealed several risk and protective factors for dementia. The
development of improved population studies over the years has
characterized with great detail which environmental factors confer
risk or protection, thus opening the possibility of designing pre-
ventive strategies. Several vascular, lifestyle, and genetic risk factors
have been recognized and they may act both independently and
by potentiating each other (Kivipelto et al., 2008). Epidemiologi-
cal and biological evidences strongly underlined the importance
of the vascular component in AD pathology, (Ligthart et al., 2010)
and diabetes, hypertension, and high blood cholesterol levels have
been shown to enhance the risk for AD (Imtiaz et al., 2014). In
addition to those, other conditions prone to converge into AD
have been identiﬁed, among them traumatic brain injury (Shively
et al., 2012), ischemia/hypoxia (Zhang and Le, 2010), neuroin-
ﬂammation (Ferreira et al., 2014), and metabolic abnormalities
coursing with decreased brain glucose uptake (Gong et al., 2006).
Figure 2 displays a list of etiological factors in human AD.
Based on these risk indicators, the possibility of predicting who
will develop AD is very modest; however, the relevance of these
correlations lies in that they give clues about pathways/processes
leading to AD. Some of those pathways have been somehow con-
ﬁrmed by genome-wide association studies (GWAS). Over the last
three to ﬁve years, GWAS (with continuous pooling of larger num-
ber of samples) have identiﬁed common loci (typically frequencies
of 10–50%) which have modest effects on risk (with odds ratios
in the 1.1–2.0 range; Hardy et al., 2014). In broad terms, GWAS
identiﬁed cholesterol metabolism, innate immune system, and
endosomal vesicle recycling as important contributors to AD. As
some of the APP processing occurs in endosomal compartments,
proteins participating in vesicle trafﬁc (SORL1, PICALM, and
BIN1) are worth being further characterized (Hardy et al., 2014).
Very little is known about the therapeutical implications of the
discovery but it seems plausible that impairment of vesicle recy-
cling would have detrimental consequences in secretory and/or
autophagy pathways.
Before these recent genetic studies, a large amount of evidence
suggested a pathogenic link between disruptions in cholesterol
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FIGURE 2 | Scheme of etiological factors and challenges in AD research.
Pathogenesis: epidemiological and genetic ﬁndings uncovered several major
mechanisms leading to AD pathogenesis. Main AD pathological hallmarks are
deposition of Aβ and p-tau in the brain. It is unquestionable that AD starts
with Aß pathogenesis in familial AD (FAD) cases. The current knowledge
suggests that tau pathology is a later event in the disease.
metabolism and AD. The strongest known genetic risk factor for
sporadic AD is the presence of the E4 allele of the apolipoprotein E
(ApoE), which was already detected in 1993 (Corder et al., 1993).
ApoE is the major carrier of cholesterol in the central nervous
system (CNS) and compared to other apoE isoform carriers, indi-
viduals with one or two copies of apoE4 have a higher risk to
developAD. Since the discovery of ApoE4 as a major risk factor for
AD, considerable efforts have been made in linking this molecule
to Aβ metabolism, aggregation, and deposition. An increased
plaque deposition has been observed in apoE4 individuals and
in animal models of brain amyloidosis carrying the human apoE4
(Schmechel et al., 1993). ApoE4 has been shown to potentiate Aβ
toxicity in vitro (Cedazo-Minguez et al., 2001; Manelli et al., 2007)
and in animal models (Bales et al., 1999). Studies in microglia
have shown that ApoE3 cells can degrade Aβmore efﬁciently than
ApoE4 cells. Moreover, ApoE4 binds Aβ with lower afﬁnity than
ApoE3, suggesting that ApoE4 might be less efﬁcient in mediating
Aβ clearance (LaDu et al., 1994). On the other hand, the con-
tribution of ApoE4 to tau hyperphosphorylation remains poorly
understood.
A reduced capacity for neuronal delivery of cholesterol of
apoE4 is believed to have consequences for synaptogenesis and
repair mechanisms, and it is likely to directly contribute to dis-
ease progression. This notion is supported by GWAS, where in
addition to apoE, several other candidate genes related to choles-
terol synthesis, transport, uptake, or metabolism were identiﬁed
(i.e., ABCA7, ABCA1, CLU, CYP46A1; Hardy et al., 2014). New
efforts are necessary to understand the underlying mechanisms, as
well as to discern if regulation of brain cholesterol metabolism has
therapeutic potential.
Neuropathological analysis of AD brains has implicated the
complement cascade in relation to AD pathogenesis. Now, genetic
analysis has clearly shown that variability in innate immunity is an
important determinant of AD riskwith several loci pointing to this
system. Inﬂammation has been proposed as an early pathogenic
event in the disease (Wilcock and Grifﬁn, 2013). Elevated levels of
complement factors in cerebrospinal ﬂuid (CSF) and microglial
activation markers have been described in AD brains, but longi-
tudinal data that classify these alterations in relation to onset of
amyloid deposition and tau phosphorylation are lacking. Since
inﬂammatory responses can have both beneﬁcial and detrimental
effects on the brain (Rivest, 2009), it would be instrumental to
delineate ways to regulate neuroinﬂammation.
We have considerable information on different pathways con-
tributing to the disease. Together, epidemiological and genetic
screenings of AD individuals have categorized insulin resistance,
deﬁcits in cholesterol transport, hypertension, and neuroinﬂam-
mation as potential factors in AD physiopathology. One of the
challenges for the future would be to discern the overlapping,
intersecting or synergic mechanisms leading to brain Aβ accumu-
lation, neuronal tau hyperphosphorylation and synaptic deﬁcits.
The existence of variant pathways to AD is probably reﬂecting the
heterogeneous etiology of the disease. It is likely that alteration
in different pathways would result in various patient subgroups,
which should be treated individually and differentially recruited in
clinical trials. The identiﬁcationof patient subtypes,with homoge-
nous etiology and prognosis, will result in more accurate and
personalized treatments. Intensifying innovative basic research
will also result in the identiﬁcation of novel biomarkers for sub-
typing AD, which is crucial for accurate diagnosis and medicinal
interventions.
MULTIPLE WAYS OF “CURING” ANIMAL AD MODELS
Apart from those affecting Aβ production/processing or those
reducing hyperphosporlated tau, a variety of drugs with different
modes of action were proved to be efﬁcacious in AD models
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(Table 1). The battery of effective compounds in animal models
for AD is continuously increasing. As example, the last two 2013
volumes of the specialized journal, Journal of Alzheimer’s Disease
have been reviewed (volumes 36 and 37). The main message from
selected articles – including literal sentences – is provided below.
Carvajal et al. (2013) show that tetrahydrohyperforin, a semi-
synthetic derivative of the phytochemical hyperforin, decreases
cholinergic markers associated with Aβ plaques and caspase-3
activation in AβPP/PS1 mice. This phytochemical is found in
St. John’s wort (Hypericum perforatum), which has been con-
sidered herbal medicine since the ancient Greeks (Klemow et al.,
2011) and is apparently helpful as antidepressant, antibacterial,
antiviral, antineoplastic, anti-inﬂammatory, antioxidant, and neu-
roprotective (Dinamarca et al., 2006; Grifﬁth et al., 2010). As a
further AD-related beneﬁt, the compound induces mitochon-
drial dynamics and prevents mitochondrial Ca2+ overload after
Aβ and Aβ–AChE complex challenge in rat hippocampal neurons
(Zolezzi et al., 2013). Cheng et al. (2013) show that nicotinamide
mononucleotide adenylyltransferase 2 affects tau phosphorylation
by regulating the activity of protein phosphatase PP2A, and sug-
gest that this enzyme may serve as a potential target in arresting
AD-like tau pathologies. Mitochondria-targeted plastoquinone
antioxidant SkQ1 prevents Aβ-induced impairment of long-term
potentiation in rat hippocampal slices. Authors summarize that
“in vivo and in vitro injection of SkQ1 compensates for Aβ-induced
oxidative damage of long-term synaptic plasticity in the hippocam-
pus, which is considered to be the main reason of memory loss
and impairment of other cognitive functions associated with AD.”
According to the authors, “SkQ1 may be considered as a promis-
ing candidate for the treatment of early-stage Alzheimer’s disease.”
Olazarán et al. (2013) show that in advanced AD patients, brain
stimulation with radio electric asymmetric conveyer technology
may improve motor deterioration. Previously,Mannu et al. (2011)
had demonstrated that radio electric asymmetric brain stimula-
tion improves behavioral and psychiatric symptoms in AD. By
measuring Aβ induction of inducible nitric oxide synthase, Dur-
sun et al. (2013) suggest a crosstalk between Aβ pathology and
vitamin D receptor and that vitamin D supplementation should
be considered in both treatment and prevention of AD. Veszelka
et al. (2013) show that “docosahexaenoic acid can protect not only
neurons but also the other elements of the neurovascular unit from the
toxic effects of Aβ42 and this effect may be beneﬁcial in AD.” Saydoff
et al. (2013) report that “a uridine prodrug improves memory in
Tg2576 and in the double mutant Tg2576 x P301L (point mutation
in tau) mice and reduces pathological factors associated with AD in
related models.”
Special attention merits the report by Wiesmann et al. (2013a)
on improved spatial learning strategy and memory in aged
Alzheimer AβPPswe/PS1dE9 mice on a multinutrient diet, as
this diet is similar to that in a commercial product that was
about to be approved for use in humans. As of March 2014, the
www.souvenaid-us.com site indicates that this product is intended
for human use:
“. . . is a unique nutritional approach providing key nutrients
to help support memory in aging adults” and “. . . contains Fort-
asynConnect, a patented combination of nutrients which includes
omega-3 fatty acids, choline, uridine monophosphate and a mixture
of antioxidants and B vitamins. The product is not yet available for
purchase as it is being further researched and developed.”
Zhao et al. (2013) reported that “an early intervention with
an estrogen receptor β-selective phytoestrogenic mixture, referred to
as the (phyto-β-SERM) formulation, which exhibits 83-fold higher
binding selectivity for the estrogen receptor subtype β (ERβ) than
for ERα, prolongs survival, improves spatial recognition memory,
and slows progression of amyloid pathology in a female AD mouse
model.”
These papers represent a sample from just 6 months of a
single journal; they reﬂect the enormous scientiﬁc task devoted
to AD in hundred of laboratories around the world, and
support the view that targeting different proteins in differ-
ent pathways is successful when using transgenic AD mouse
models
It is worth noting two epidemiological studies in these two
volumes of the Journal of Alzheimer’s Disease. In a cross-sectional
and longitudinal study,Qiu et al. (2013) reported that“angiotensin
converting enzyme inhibitors, especially peripherally acting ones, are
associated with a reduced risk of AD in the absence of apoE4, but
had no such effect in those carrying the apoE4 allele.” This paper is
noticeable because it is an example of the various papers showing,
also inAD mouse models, that peripheral interventions may result
in CNS beneﬁts. Even maternal breastfeeding has been analyzed
among a cohort of elderly British women to ﬁnd that “those who
breastfed had lower AD risk than women who did not breastfeed”
(Fox et al., 2013).
THE GAP BETWEEN MOUSE MODELS AND HUMAN
PATIENTS
The reasons for the poor translation of pre-clinical into clini-
cally successful interventions to combat the disease are unknown.
The lack of good predictive animal models, good biomarkers for
disease progression, and well-deﬁned target populations in clini-
cal trials are strong barriers for demonstrating potential anti-AD
beneﬁts. A list of pros and cons of using animal models and
patients (Table 2) reﬂects key differences that explain, in part,
the difﬁculties in translating pre-clinical ﬁndings to patients.
It is likely that the use of simple animal models reﬂecting a
single aspect of AD is not enough to mimic the disease, and
thus, to develop new treatments. Another possibility is that Aβ
and tau pathologies are endpoints for different disease-driving
mechanisms. Thus, achieving a successful inhibition of Aβ and
tau pathologies may not result in a successful anti-AD therapy.
Considering the heterogeneity of AD, it is probable that a multi-
target approach will be necessary. To create better animal models
for AD, an advancement in the understanding of the molecular
neuropathological mechanisms would be desirable. Another key
issue is the lack of neuronal death in the main animal AD mod-
els, which contrasts with the patient’s decline in CNS neuronal
number. Further research breakthroughs are needed for the devel-
opment of models reﬂecting the heterogeneity of the disease. Also,
new biomakers to identify disease populations and disease pro-
gression are crucial to adjust clinical trials, and hence, evaluate the
real potential of tested compounds. Yet, there is chance to ﬁnd hid-
den clues in the huge amount of information obtained in animal
models.
Frontiers in Pharmacology | Neuropharmacology June 2014 | Volume 5 | Article 146 | 6
Franco and Cedazo-Minguez Alzheimer’s disease therapy
Ta
b
le
2
| D
iff
er
en
ce
s
b
et
w
ee
n
A
D
m
o
d
el
s
an
d
h
u
m
an
A
D
.
A
D
an
im
al
m
o
d
el
s
Pa
ti
en
ts
P
ro
s
C
o
n
s
P
ro
s
C
o
n
s
G
oo
d
fo
r
pr
e-
cl
in
ic
al
as
sa
ys
Th
ey
ov
er
ex
pr
es
s
m
ut
an
t
ve
rs
io
ns
of
hu
m
an
pr
ot
ei
ns
;t
he
re
fo
re
,t
he
y
ar
e
no
t
su
ita
bl
e
m
od
el
s
fo
r
th
e
m
os
t
co
m
m
on
fo
rm
of
A
D
(la
te
on
se
t)
Th
ey
di
sp
la
y
th
e
re
al
pa
th
ol
og
y
Fi
na
ld
ia
gn
os
is
do
ne
po
st
-m
or
te
m
Fe
as
ib
ili
ty
of
ob
ta
in
in
g
tr
an
sg
en
ic
s
w
ith
co
gn
iti
ve
de
ﬁc
its
Th
ey
do
no
t
di
sp
la
y
ne
ur
on
al
lo
ss
;t
he
re
fo
re
,t
he
y
ar
e
no
t
go
od
fo
r
te
st
in
g
ne
ur
op
ro
te
ct
io
n
in
A
D
C
er
eb
ro
sp
in
al
ﬂu
id
av
ai
la
bl
e
La
ck
of
bi
om
ar
ke
rs
fo
r
pa
tie
nt
st
ra
tiﬁ
ca
tio
n
(A
D
su
re
ly
in
cl
ud
es
di
ffe
re
nt
un
de
rly
in
g
pa
th
ol
og
ie
s)
Tr
an
sg
en
ic
s
ar
e
go
od
m
od
el
s
fo
r
ea
rly
-o
ns
et
A
D
(d
ue
to
m
ut
at
io
ns
in
ge
ne
s
fo
r
pr
es
en
ili
ns
or
A
P
P
)
P
ilo
tc
lin
ic
al
tr
ia
ls
ar
e
fe
as
ib
le
.I
nd
ee
d,
on
e
m
ay
w
on
de
r
w
hy
th
er
e
is
m
or
e
m
on
ey
al
lo
ca
te
d
to
st
ud
ie
s
in
m
ic
e
th
an
in
cl
in
ic
al
tr
ia
ls
La
ck
of
en
ou
gh
bi
om
ar
ke
rs
to
as
se
ss
ef
ﬁc
ac
y
of
in
te
rv
en
tio
n
in
cl
in
ic
al
tr
ia
ls
Tr
an
sg
en
ic
s
ar
e
go
od
fo
r
te
st
in
g
co
gn
iti
ve
en
ha
nc
em
en
t
st
ra
te
gi
es
Li
m
ite
d
av
ai
la
bi
lit
y
of
pa
tie
nt
s,
sp
ec
ia
lly
di
fﬁ
cu
lt
is
to
ob
ta
in
an
ho
m
og
en
eo
us
pa
tie
nt
po
pu
la
tio
n
In
te
rv
en
tio
ns
m
ay
st
ar
t
be
fo
re
pa
th
ol
og
y
ap
pe
ar
s
In
te
rv
en
tio
ns
(in
cl
in
ic
al
tr
ia
ls
)s
ta
rt
af
te
r
di
ag
no
si
s;
ob
vi
ou
sl
y
tr
ea
tm
en
ts
ca
nn
ot
st
ar
t
be
fo
re
cl
in
ic
al
sy
m
pt
om
s
ap
pe
ar
A
ni
m
al
s
m
ay
be
si
m
ul
ta
ne
ou
sl
y
tr
ea
te
d
an
d
tr
ai
ne
d
to
le
ar
n
(fo
r
in
st
an
ce
in
th
e
M
or
ris
w
at
er
m
az
e
te
st
)
C
lin
ic
al
tr
ia
ls
d
o
n
o
t
in
cl
u
d
e
si
m
u
lt
an
eo
u
s
tr
ai
n
in
g
to
le
ar
n
(i
n
te
rv
en
ti
o
n
s
in
an
im
al
A
D
m
o
d
el
s
d
o
in
cl
u
d
e
tr
ai
n
in
g
)
Tr
ai
n
in
g
/c
o
g
n
it
iv
e
ta
sk
s
ca
n
b
e
in
cl
u
d
ed
al
o
n
g
th
er
ap
eu
ti
ca
li
n
te
rv
en
ti
o
n
s
M
an
y
in
te
rv
en
tio
ns
pr
ov
id
e
po
si
tiv
e
re
su
lts
M
an
y
in
te
rv
en
tio
ns
in
cl
in
ic
al
tr
ia
ls
pr
ov
id
e
in
co
nc
lu
si
ve
/n
eg
at
iv
e
re
su
lts
M
an
y
in
te
rv
en
tio
ns
la
ck
th
e
ph
ar
m
ac
ok
in
et
ic
s
of
th
e
dr
ug
an
d
da
ta
on
br
ai
n
pe
ne
tr
an
ce
C
S
F
di
fﬁ
cu
lt
to
ta
ke
C
S
F
av
ai
la
bl
e
Th
e
ta
bl
e
is
co
ns
tr
uc
te
d
th
in
ki
ng
of
pr
os
an
d
co
ns
in
in
te
rv
en
tio
ns
in
vo
lv
in
g
an
im
al
s
an
d
hu
m
an
s.
In
bo
ld
:p
ro
m
is
in
g
st
ra
te
gi
es
al
be
it,
to
ou
r
kn
ow
le
dg
e,
no
t
ex
pl
oi
te
d
in
cl
in
ic
al
tr
ia
ls
.
www.frontiersin.org June 2014 | Volume 5 | Article 146 | 7
Franco and Cedazo-Minguez Alzheimer’s disease therapy
LESSONS FROM PROSPECTIVE STUDIES:
NEUROPROTECTION BEFORE THE DISEASE
Clinical trials for neuroprotection are extremely difﬁcult to imple-
ment and novel strategies are being sought to be able to detect
any slowing-down of disease progression. This means that, as of
today, clinical trials with patients with dementia should concen-
trate on symptom improvement irrespective of whether it comes
from neuroprotection or from enhancing cognition. Epidemio-
logical studies are important as they provide information about
neuroprotection before the disease appears or, in other words,
what life style, diet habit, or chronic drug treatment may delay
the onset of clinical symptoms of cognitive impairment (see the
previous section). Freedman et al. (2012) reported the results of
the follow-up of 5,148,760 person-years between 1995 and 2008,
in which a total of 33,731 men and 18,784 women died. The con-
clusion of this large, prospective study is that coffee consumption
inversely associates with total and cause-speciﬁc mortality. Cof-
fee consumption may be relevant for neurodegenerative diseases
for its caffeine content and its diverse and (often) positive central
actions.
A relatively recent study shows in Drosophila models of Parkin-
son’s disease (PD) that decaffeinated coffee and nicotine-free
tobacco provide neuroprotection (Trinh et al., 2010). Again, these
animal models do not seem appropriate to extrapolate the results
to humans. In fact, it has been shown that humans taking nico-
tine and caffeine are less prone to have PD. Ascherio et al. (2001)
workingwith data from theHealth Professionals’Follow-Up Study
and the Nurses’ Health Study cohorts (47,351 men and 88,565
women) identiﬁed a protective effect of moderate doses of caf-
feine on risk of PD. In parallel, data analyzed by Ross et al. (2000)
from 30 years of follow-up of 8004 Japanese–American men (aged
45–68 years), enrolled in the prospective, longitudinal Honolulu
Heart Program between 1965 and 1968, showed that higher coffee
intake is associated with a signiﬁcantly lower incidence of PD. The
study of environmental, life style, and physical precursors of clini-
cal PD from the Honolulu-Asia Aging Study indicates that factors
showing an inverse association with PD included coffee intake and
cigarette smoking (Abbott et al., 2003).
As one may imagine, caffeine, which is the world most con-
sumed psychoactive molecule, was considered as a candidate to
either increase or decrease the chances of having dementia. Maia
and de Mendonça (2002) followed 59 AD patients and 59 controls
to ﬁnd using a logistic regression model, that caffeine intake in
the previous 20 years was associated with a signiﬁcantly lower risk
for AD. The inverse correlation was conﬁrmed by Eskelinen and
Kivipelto (2010) by following for more than 20 years participants
of the Cardiovascular Risk Factors, Aging and Dementia (CAIDE)
study (61 cases were identiﬁed as demented – 48 having AD). The
study demonstrates that coffee drinkers had lower risk of demen-
tia and AD compared with those drinking no or only little coffee
(datawere indeed adjusted for depressive symptoms, apoE 4 allele
and for demographic, vascular, and lifestyle factors). The lowest
risk (65% decrease) was found in people who drank 3–5 cups per
day. A very relevant conclusion of this study is that coffee drink-
ing at midlife is associated with a decreased risk of dementia/AD
later in life (Eskelinen and Kivipelto, 2010). Therefore, it seems
that caffeine could be neuroprotective and that this could result in
preserved cognition.Would the situation be similar once dementia
has started?
NEUROPROTECTION VERSUS COGNITIVE ENHANCEMENT
Protecting neurons implies not only to avoid cell death but also
to preserve a functional synaptic network; therefore, the term
“neuroprotection” should be extensive to both avoid neuronal
and synaptic losses. Thus, a relevant question may be formu-
lated as “what comes ﬁrst”: is cognitive enhancement preventing
neurodegeneration (either spine or neuron loss) or is neuropro-
tection that helps in retaining/retrievingmemories? To answer this
question, approaches to uncouple neuroprotection from cognitive
enhancement would be necessary. As an analogy, understanding
mitochondrial functionhad to await thedrugs that uncoupledoxy-
gen consumption fromATP synthesis. While oxygen consumption
leads to ATP replenishment two different processes occur, namely
reduction of oxygen with proton pumping across the mitochon-
drial membranes and oxidative phosphorylation of ADP to ATP.
Uncouplers and the Nobel Laureate (in Chemistry in 1978) Peter
D.Mitchell were the clue to solve the conundrumof mitochondrial
operation in electron transport and synthesis of ATP2.
In the AD ﬁeld, accumulating reports show beneﬁcial effects
of multiple compounds on cognition in animal models. However,
since theseADmodels donot showneuronal loss, it is expected that
the reported effects on cognition result from improving neuronal
performance. In humans, AD is characterized by a substantial
neuronal loss, resulting in reduced brain volume; thus it is unclear
that the neurodegenerative processes occurring in AD are com-
parable to those obtained in AD animal models. To evaluate the
proper effect of drugs on neuroprotection, it would be necessary
to dissect out effects on neuronal death from those on cognition.
LESSONS FROM EFFICACIOUS AND NON-EFFICACIOUS
MOLECULES IN RED WINE
Life style surely impacts on the incidence of a variety of diseases.
Mediterranean diet is considered the best ally to delay or pre-
vent the occurrence of diabetes, hypertension, obesity, etc. One
key component of the diet is moderate wine consumption and
resveratrol has been identiﬁed as a key compound for wine-related
health beneﬁts. For these reasons, wine and resveratrol have been
considered as anti-AD agents.
Resveratrol is derived from plants and is found in highest levels
in redwine and the skin of red grapes. TheCopenhagenCityHeart
Study (Truelsen et al., 2002) reported that monthly and weekly
consumption of red wine is associated with a lower risk of demen-
tia. Subsequently, clinical studies of resveratrol are undertaken to
evaluate the safety, tolerability, and effectiveness of resveratrol on
CSF and other biomarkers for the treatment of AD. To give an
example, the title of the NCT01504854 study is: “Phase II Study
to Evaluate the Impact on Biomarkers of Resveratrol Treatment in
Patients with Mild to Moderate AD.” Hopeful as it is, such stud-
ies with resveratrol are undermined by other clinical studies to
assess the usefulness of resveratrol for (http://clinicaltrials.gov):
enhancing oocyte quality in in vitro fertilization procedures; type
2Some scientists are reluctant to accept Mitchell’s chemiosmotic hypothesis;
however to date it is the one that best describes the phenomenon.
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II diabetes, obesity, non-alcoholic fatty liver disease, impaired
glucose tolerance, insulin sensitivity and preservation of beta
cell function following gestational diabetes, Friedreich’s ataxia,
primary and secondary prevention of cardiovascular disease, vas-
cular health in postmenopausal women and colon cancer. Either
these ailments have a common factor or resveratrol is a miracle
compound. Still, efﬁcacy of resveratrol in AD enters into the rule
that almost any drug is efﬁcacious in AD mouse models. But are
there other anti-AD ingredients in red wine?
Ho et al. (2013), in a recent and exhaustive study, mea-
sured the accumulation of polyphenols in the rat brain following
oral dosage with a Cabernet Sauvignon red wine and tested
brain-targeted polyphenols for potential beneﬁcial AD disease-
modifying activities. They observed that, among brain-targeted
polyphenol metabolites, quercetin-3-O-glucuronide, was able to
reduce the generation of Aβ peptides by primary neuronal cul-
tures from the Tg2576 AD mouse model. Interestingly, another
polyphenol compound, malvidin-3-O-glucoside, did not have
an effect and therefore constitutes one of the few examples of
reported negative results. The quercetin conjugate also improved
AD-type deﬁcits in hippocampal basal synaptic transmission and
long-term potentiation. The authors propose that quercetin-3-O-
glucuronide: “may simultaneously modulate multiple independent
AD disease-modifying mechanisms and, as such, may contribute to
the beneﬁts of dietary supplementation with red wines as an effective
intervention for AD.” Intriguingly, the same laboratory reported
that different wines with different polyphenolic composition sig-
niﬁcantly attenuated the development of AD-type brain pathology
and memory deterioration in a transgenic AD mouse model (Ho
et al., 2009), postulating thepossibility todevelop a“combination of
dietary polyphenolic compounds for AD prevention and/or therapy
by modulating multiple Abeta-related mechanisms.” Actually, this
leads us back to square one, i.e., different wines, different diet sup-
plements, different drugs, etc., are all efﬁcacious as anti-AD agents
in animal models. The novelty is that the data in this laboratory
point toward different mechanisms that may be independently
(perhaps synergistically?) helpful.
LESSONS FROM ADRENERGIC-RECEPTOR-BASED
INTERVENTIONS
Some lessons could be learned from studies pointing to adrenergic
receptors as targets in cognitive disorders. Whereas positive results
have been described in animal models, adrenergic drugs have not
reached themarket for combatingAD.However, a neuroprotective
role for these compounds cannot be ruled out.
Adrenergic receptors are by and large the most studied
G-protein-coupled receptors (GPCRs). β-Adrenergic receptor
blockers and antagonists of histamine receptors started a revolu-
tion ending up with more than 40% of the current approved drugs
targeting GPCRs. Among those, a huge majority target adren-
ergic receptors (despite there are hundreds of GPCRs). Drugs
targeting those receptors arrived ﬁrst to patients with cardiovas-
cular diseases. Later on, they were approved for other indications.
Although the drug is not used today for this indication, propra-
nolol, a prototypic adrenergic receptor antagonist, was suggested
for the control of disruptive behavior in dementia (Weiler et al.,
1988). In the 1990s, Cowburn et al. (1993) reported disrupted
β1-adrenoceptor-G protein-coupling in the temporal cortex of
AD patients. Adrenoceptors and other GPCRs are deﬁciently cou-
pled to G proteins in brain samples from AD patients (Wang
and Friedman, 1994). Upon work with animal (rodent) models,
a multivariate link between adrenoceptors and AD pathological
hallmarks was established. Whereas Lee et al. (1997) reported
stimulation of amyloid precursor protein synthesis by adrenergic
receptors coupled to cAMP formation,Ni et al. (2006) showed that
activation of β2-adrenergic receptor accelerates amyloid plaque
formation and enhances γ-secretase activity.
Yu et al. (2010) reported that blocking β2-adrenergic receptor
attenuates acute stress-induced Aβ peptide production, and Gibbs
et al. (2010) that memory loss caused by β-amyloid protein is res-
cued by a β(3)-adrenoceptor agonist. Koutroumani et al. (2013)
recently indicated that the deletion variant of α2b-adrenergic
receptor is associated with decreased risk in AD and mild cogni-
tive impairment. Moreover, β2 adrenergic receptor, protein kinase
A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways
mediate tau pathology inAD models (Wang et al., 2013). Thathiah
et al. (2013) have even linked β-arrestin 2 to Aβ generation and γ-
secretase activity in an animal model for AD. In terms of therapy,
Katsouri et al. (2013) have tested prazosin, an α(1)-adrenoceptor
antagonist, to prevent memory deterioration in the APP23 trans-
genic mouse model of AD. Aβ(1-42) induces internalization and
degradation of β2 adrenergic receptors in prefrontal cortical neu-
rons (Wang et al., 2011). Furthermore, it has been hypothesized
that elevated norepinephrine may be an etiological factor in some
cases of AD (Fitzgerald, 2010) and Bullido et al. (2004) described
polymorphism in genes involved in adrenergic signaling associ-
ated with AD. Recently, Femminella et al. (2013) have written an
article whose title is very suggestive: “β-adrenergic receptors and
G protein-coupled receptor kinase-2 in Alzheimer’s disease: a new
paradigm for prognosis and therapy?,” as suggestive is part of the
summary of the Yu et al. (2010) review: “In the recent years, several
unexpected longitudinal and cross-sectional epidemiological stud-
ies reveal that beta-blocker treatment reduces the prevalence of AD
in patients suffering from hypertension. Now, a newly population-
based study of individuals with incident AD demonstrates that
beta-blockers are also associated with delay of functional decline.
Furthermore, accumulated convincing evidences from cell culture
experiments and animal studies have also suggested thatβ-adrenergic
receptors (β-ARs) may involve in the AD pathogenesis through effects
on amyloid-β (Aβ) production or inﬂammation.”
The above-indicated and optimistic view that adrenergic recep-
tors as targets in AD should be taken with caution. In fact, Gliebus
and Lippa (2007) highlighted that signaling via β1-adrenergic
receptors is important for the retrieval of spatial and con-
textual memories. The main adrenergic nucleus of the brain,
the locus coeruleus is activated by environmental cues leading
to norepinephrine-mediated hippocampal activation, which is
important for retrieving memories. The authors demonstrated
that although β-blockers do not impair cognition in normal sub-
jects, there was a trend for worse delayed memory retrieval in
cognitively impaired patients who were on CNS-active β-blockers.
The authors concluded: “common medications used in cognitively
impaired elderly patients can worsen cognition and that careful selec-
tion of medications may help to maximize retrieval of newly formed
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memories.” It may happen that a given adrenergic receptor antag-
onist is good for neuroprotection before AD appears but not to
improve patient’s condition. This hypothesis would be consistent
with differential mechanism for neuroprotection and for cognitive
enhancement. Moreover, two time-dependent neuroprotective
strategies may be considered: one to prevent disease and another
to prevent disease progression; indeed these two strategies would
likely be achieved by hitting different targets. Thus, caffeine and β-
blockers could delay the appearance of cognitive deﬁcits but they
may not be good for patients. In fact, caffeinated coffee is not
recommended once AD has appeared.
PHARMACOKINETICS AND MULTIMODAL DRUGS SHOULD
BE TAKEN INTO ACCOUNT
The majority of studies on potential anti-AD therapies are per-
formed on transgenic models to which the assayed substance(s)
is(are) administered. In a high percentage of these studies (i) the
actual concentration that reaches the CNS, (ii) the plasma/brain
ratio, and (iii) the half-life of the compound in blood or brain
are undetermined. These parameters are important to understand
where, when, and how a given drug is acting.
It may also occur that a given drug is acting on quite diverse
targets whose distribution in the (rodent or human) body is un-
even. For example, Okun et al. (2010) reported a very informative
study on dimebon, originally developed as an anti-histamine drug.
Dimebon seems to be a multimodal drug with many different
targets including serotonergic, α-adrenergic, and dopaminergic
receptors. The results indicate something that should be consid-
ered in drug discovery, namely that a drug with multiple targets
may result in greater beneﬁts than a “clean” drug acting only on a
given target. Furthermore, Okun et al. (2010) suggest that it is nec-
essary to understand the role of different pathways in AD and in
any other disease with complex etiologies. Such knowledge would
surely help in developing multitarget drugs.
CRITICAL ANALYSIS OF ANTI-AD THERAPEUTIC SUCCESS IN
AD MOUSE MODELS
In this article, we aimed at discussing how come such diver-
sity of targets achieves anti-AD beneﬁts in pre-clinical studies.
A common mechanism of action mediated by all these targets is
difﬁcult to envisage, and therefore it seems that different mech-
anisms may result in similar beneﬁts. Very often, the beneﬁts
reported are multiple and point to the same direction. Frequently,
a given drug/treatment improves cognition performance in one
or various cognition tests (or strengthen long-term potentiation)
and produces beneﬁts in parameters related with one of the two
main hallmarks of the disease: reduction of Aβ-containing plaques
or reduction of hyperphosphorylated tau. A priori there is not
any reason to expect that something that decreases plaques also
decreases aberrant tau phosphorylation (or vice versa). Since no
obvious relation has been provided to link these two pathologies
(plaques and tangles) in animal models, no ﬁnal conclusions may
be obtained. It would be very important to know, for example,
if a given drug that enhances cognition and reduces plaque load
in APP mice, also shows positive effects on cognition (or even
in tau pathology) in a tau mice. Even negative results would be
informative. For example, which drugs/treatments do not enhance
cognition but decrease amyloid burden or phosphorylated tau or
which type of drug reduces one of these pathologies but worsen
cognitive status.
The growing list of effective compounds curing AD mice mod-
els has only created frustration when evaluated in human trials. As
to date, good animal models for AD are lacking and more compre-
hensive and critical studies on the results with the available models
would be necessary to build high-quality knowledge.
THEMES FOR DEBATE
The success of anti-AD interventions in mouse models together
with the negative results in humans underline the gap between
our models of investigation and the real disease. Models to
develop a single AD pathological feature are incomplete (Table 2).
Accelerated AD mouse models that have plaques and cognition
deﬁcits sooner in time without neuronal loss are not necessar-
ily better models. Is it possible to create a better AD mouse
model? How could we obtain the most possible information
from the available models? A list of challenges is included in
Figure 2.
Actions leading to cognitive enhancement even in AD models
may be considered for use in humans, especially in cases in which
the drug is already in the market (drug reproﬁling programs). In
addition of reducing amyloid and tau pathologies, would it be
necessary to boost synaptic strength and cognition?
Common mechanisms in FAD and late-onset AD are not evi-
dent. Is that anti-amyloid strategies would have limited beneﬁts
only in FAD cases?
Many diverse genetic and environmental factors have been
shown to contribute to AD. This could imply that the etiology
of AD is multiple. The ﬁeld is in need of biomarkers to reﬁne cri-
teria for achieving a better patient stratiﬁcation. Are we targeting
the right population in clinical trials?
Retrospective epidemiological studies have provided evidence
for good AD preventive compounds. Some of them were tried in
humanswithnegative results.Would it be convenient to investigate
the putative effects of these compounds in prospective studies?
CHALLENGES
The discovery of genetic and environmental risk factors for AD
offers the possibility of designing preventing strategies, but also
of understanding how the disease starts and thus, of ﬁnding
novel disease-modifying therapies. It is still questionable if anti-
Aβ-based therapies will provide the expected beneﬁts. Perhaps,
anti-Aβ approaches would only work for FAD cases, where the
amyloid pathogenesis is prominent. Anti-tau-based therapies have
also failed in clinical trials, thus raising the possibility that anti-tau
interventions come too late to prevent neurodegeneration in AD.
One of the biggest challenges for AD research is to create good
animal models that adequately reﬂect both disease etiology and
disease progression. Accumulating evidence demonstrate that the
current models, based in massive overexpression of Aβ or p-tau,
are not ﬁt for purpose. Since AD etiology seems to be heteroge-
neous (several variant genetic and lifestyle risk factors reported),
it would be instrumental to have speciﬁc biomarkers for each sub-
group of patients. Advances in all those aspects will bring the
possibility of personalized preventive and curative strategies.
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